BNTX logo

BioNTech SE (BNTX)

$91.09

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BNTX

Market cap

$22.89B

EPS

-5.52

P/E ratio

--

Price to sales

8.18

Dividend yield

--

Beta

1.316953

Price on BNTX

Previous close

$89.33

Today's open

$89.48

Day's range

$88.50 - $92.11

52 week range

$79.52 - $124

Profile about BNTX

CEO

Sahin Ugur

Employees

6772

Headquarters

Mainz,

Exchange

Nasdaq Global Select

Shares outstanding

251325340

Issue type

American Depository Receipt

BNTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BNTX

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring

BioNTech's oncology pipeline could help it make a dent in this large and growing market. However, there is one thing investors should consider before initiating a position.

news source

The Motley Fool • Jul 23, 2026

news preview

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

news source

GlobeNewsWire • Jul 21, 2026

news preview

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock

On July 8, the Ark Genomic Revolution ETF sold roughly $7.4 million worth of BioNTech stock. Cathie Wood's ETF has now almost completely sold its entire position in BioNTech.

news source

The Motley Fool • Jul 14, 2026

news preview

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

BioNTech has held confidential talks with potential buyers about ​the German sites that the ‌COVID‑19 vaccine maker plans to close, which has now grown to four locations, ​the Handelsblatt newspaper reported on ​Friday.

news source

Reuters • Jul 3, 2026

news preview

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

U.S. pharmaceutical company ​Moderna is interested ‌in investing in production facilities in ​Germany, with ​an eye on ⁠plants that its ​German rival ​BioNTech plans to close, CEO Stephane Bancel ​told the ​German business daily Handelsblatt ‌on ⁠Wednesday.

news source

Reuters • Jun 17, 2026

news preview

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

news source

Zacks Investment Research • Jun 4, 2026

news preview

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.

news source

Zacks Investment Research • Jun 1, 2026

news preview

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”). The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%).

news source

GlobeNewsWire • May 30, 2026

news preview

This Biotech's Cancer Portfolio Could End Its Rough Patch

The drugmaker is looking to its oncology pipeline to drive its next leg of growth.

news source

Barrons • May 27, 2026

news preview

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option Continued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart.

news source

GlobeNewsWire • May 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in BioNTech SE

Open an M1 investment account to buy and sell BioNTech SE commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BNTX on M1